A urine dipstick reading of glucose is usually mundane, but a few presentations behind it are emergencies. The classic trap is the lean young person with osmotic symptoms and weight loss: that is new type 1 diabetes and may already be ketoacidotic, so it needs a same-day capillary glucose and ketone check rather than a routine fasting test — and in anyone under 18, NICE NG18 asks for same-day referral to the paediatric diabetes team. The NG12 link is pancreatic cancer: new diabetes after 60 with weight loss is one of the listed combinations for urgent direct-access pancreatic imaging, and jaundice at 40 or over is a direct referral. In patients on SGLT2 inhibitors, the MHRA has warned that ketoacidosis may occur with near-normal glucose, so unwellness, not the glucose number, triggers the ketone check. Pregnancy lowers the renal threshold, which is why NG3 sets specific dipstick thresholds rather than acting on any trace.

Everything in glycosuria flows from one idea: the kidney spills glucose either because the blood level is too high or because the threshold for reabsorption is too low. That single split — hyperglycaemic versus normoglycaemic glycosuria — decides whether the patient has diabetes or simply a benign low renal threshold. Because the dipstick cannot tell these apart, the indispensable next step is always a blood test, and the commonest error is to reassure (or alarm) a patient on the strength of the urine result alone. The reverse error is just as real: a negative dipstick does not rule out diabetes, so it has no place as a screening test in someone with symptoms or risk factors.

The history quickly biases you towards one side of the split. Osmotic symptoms argue for genuine hyperglycaemia and prompt confirmatory bloods without delay, while the same picture with rapid weight loss or vomiting escalates to a same-day pathway. NICE NG17 reminds us that type 1 diabetes in adults usually (but not always) shows one or more of ketosis, rapid weight loss, onset under 50, BMI under 25, and a personal or family history of autoimmune disease — and that age or BMI alone should not be used to rule it in or out. The single most important question in modern practice is the drug history: a patient on an SGLT2 inhibitor is expected to have glucose in the urine, and missing that leads to needless work-ups. Pancreatic and endocrine clues flag the secondary diabetes that needs its own investigation.

The differential keeps the benign and the serious causes side by side. Most glycosuria with hyperglycaemia is type 2 diabetes, but the list must stay open to type 1 in the young or lean (and to slowly evolving autoimmune diabetes in adults), to monogenic diabetes where the family history is striking, to the secondary causes — with pancreatic cancer flagged under NG12 — and to the entirely benign normoglycaemic causes. Fanconi syndrome is the clue to look beyond glucose: if the urine is also losing amino acids, phosphate and bicarbonate, the problem is the proximal tubule — review nephrotoxic drugs, and consider a myeloma screen only with additional features such as anaemia, renal impairment, hypercalcaemia, bone pain, proteinuria or other paraprotein clues.

Investigation is built around a laboratory blood glucose measure. The thresholds come from the WHO (HbA1c 48 mmol/mol from the 2011 report; fasting 7.0 and random 11.1 mmol/L from the 2006 report), and a single abnormal value needs repeating unless the patient has symptoms. HbA1c reflects the previous two to three months, so it is falsely reassuring in rapidly evolving type 1 diabetes, in children, and in pregnancy, and it is distorted by anything that changes red cell lifespan. If the patient is unwell, the work-up shifts immediately to ketones and hospital assessment. Where plasma glucose is normal but glycosuria persists, renal glycosuria becomes likely once SGLT2 inhibitors, pregnancy and other tubular abnormalities have been considered — and the discipline is then to stop and reassure rather than over-investigate. The secondary screens, including NG12 pancreatic imaging, are deployed when the history points to them.

Referral is dominated by two urgent routes and one cancer pathway. Suspected DKA or HHS go to hospital immediately (999), and any child with suspected type 1 diabetes is a same-day specialist referral under NG18 — never an oral-agent start or a "come back for fasting bloods" plan in primary care. A well adult with a clinical diagnosis of type 1 still needs insulin started promptly by the specialist team. New diabetes after 60 with weight loss triggers the NG12 pancreatic-imaging route, and it is worth remembering that the imaging is direct access — the GP requests it. Around these, routine endocrinology handles diagnostic uncertainty and secondary causes, nephrology handles tubular disorders, and gestational diabetes goes to the joint antenatal clinic.

The therapeutic principle is to treat the underlying state, never the dipstick. Renal glycosuria and the glycosuria of SGLT2 inhibitors need nothing more than explanation. Confirmed type 2 diabetes now enters the NG28 (February 2026) pathway — implemented locally via the local formulary — where modified-release metformin plus an SGLT2 inhibitor is the recommended starting combination for most adults because of the heart and kidney protection the SGLT2 class brings, with metformin alone considered where frailty makes volume depletion or hypotension a real risk. Suspected type 1 must go to specialist care for insulin — trialling oral agents is dangerous. Urine glucose has no role in monitoring modern diabetes, and in anyone taking an SGLT2 inhibitor it is permanently positive.

Lifestyle advice is tailored to which side of the split the patient sits on. For benign renal glycosuria the highest-value intervention is reassurance, sparing the patient unnecessary diets and repeat tests. For non-diabetic hyperglycaemia, a structured lifestyle programme and periodic retesting reduce progression. For confirmed type 2 diabetes the familiar package — weight management, dietary change, activity and smoking cessation — supports glycaemic and cardiovascular control. Patients on SGLT2 inhibitors need specific counselling on genital hygiene, sick-day rules and ketone awareness, because their glycosuria is intentional but carries its own small risks. Driving obligations depend on treatment and licence group, so check the current DVLA guidance rather than relying on memory.

Safety-netting closes the two ways glycosuria goes wrong. The first is under-calling an emergency: osmotic symptoms with weight loss, vomiting or drowsiness — or any unwell patient on an SGLT2 inhibitor — needs a same-day ketone and glucose assessment for DKA. The second is the missed cancer: new diabetes in an older adult with weight loss should never be filed as benign without considering NG12 pancreatic imaging. For the genuinely normoglycaemic patient, the safety-net is the opposite — firm reassurance, a clear coded diagnosis and discharge, so a benign dipstick does not become a lifetime of anxious re-testing. In the SCA, explaining the kidney threshold in plain language and naming the specific symptoms that should bring the patient back the same day shows both clinical reasoning and shared understanding.